Latest Us Market News

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Pure Resources Limited has entered a legally binding R&D collaboration with Rice University to develop cutting-edge carbon nanotube fibre thermal management systems using graphite from its Garnet Hills Project. The partnership includes joint intellectual property ownership and a planned $3 million equity placement to fund exploration and downstream initiatives.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

AML3D has successfully commissioned a large-scale ARCEMY X 6700 metal 3D printer at US defence supplier FasTech, completing a $1.7 million order and signalling a strategic expansion in the US industrial manufacturing market.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Latrobe Magnesium has locked in a US$2 million non-dilutive prepayment from its US distribution partner to accelerate commissioning of its Demonstration Plant, aiming for first magnesium deliveries in late 2026.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.

Ava Risk Group has announced a $7 million strategic investment from US-based Hale Capital to fuel its expansion into the US federal security market and accelerate product development. This partnership aims to position Ava as a global leader in critical infrastructure protection with a strong US presence.

Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.

InFocus Group Holdings has completed Codexa, a proprietary sweepstakes casino platform targeting the booming US market, with plans for licensing and potential sale.

Ava Risk Group secures key government contracts and expands its technology trials in Australia, the US, and the Middle East during Q3 FY2026, reinforcing its position in critical infrastructure security.